Physician profile
Yar Mohammad
NPI 1316962301
$2,182.86
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,777 · 2020: $304 · 2021: $40.94 · 2022: $60.88.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $330.78 | 2019 | |
| Lundbeck LLC | $299.22 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $283.93 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $270.81 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $227.01 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $215.45 | 2019-2022 | |
| Allergan, INC. | $163.15 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $135.70 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $103.74 | 2019 | |
| Shire North American Group INC | $33.37 | 2019 | |
| Neos Therapeutics, LP | $31.67 | 2019 | |
| Adlon Therapeutics L.P. | $30.79 | 2020 | |
| Supernus Pharmaceuticals, INC. | $20.13 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.02 | 2019 | |
| Vertical Pharmaceuticals, LLC | $18.09 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yar Mohammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.